ClinicalTrials.gg
TerminatedNCT05600426TransITUpdated Oct 19, 2026

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

A Phase 3 interventional study of cyclosporine and Matched Unrelated Donor Hematopoetic Stem Cell Transplant in Severe Aplastic Anemia, sponsored by Boston Children's Hospital. Terminated at 52 sites in 2 countries. Open to participants aged 0 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Boston Children's Hospital · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Funding terminated
Updated Oct 19, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
0 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing Antilymphocyte Serum in Anemia, Aplastic — 3 open to participants now, 3 under way, none of them phase 3. Antilymphocyte Serum · Anemia, Aplastic.

Enrollment
8th of 20
53 · median 38
Started
2023
the only one that year
Phase 3
Only one
of the 20
Registered
18th of 20
by date
Lead sponsor
1 of 20
Boston Children's Hospital

Among the 20 studies testing Antilymphocyte Serum in Anemia, Aplastic, this one is the 8th largest by enrollment, is the only one that started in 2023, is the only one in phase 3, and was the 18th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

3 of the 20 studies testing Antilymphocyte Serum in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Antilymphocyte Serum

Antilymphocyte Serum: first FDA approval 1996 (Atgam). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 0 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing Antilymphocyte Serum in Anemia, Aplastic, or all of them as a file.
02

Study summary

Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a secondary treatment in patients who did not get better with IST, had their disease come back, or a new worse disease replaced it (like leukemia).

This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA.

The trial will also assess whether health-related quality of life and early markers of fertility differ between those randomized to URD BMT or IST, as well as assess the presence of marrow failure-related genes and presence of gene mutations associated with MDS or leukemia and the change in gene signatures after treatment in both study arms.

This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for treatment of SAA.

Read the detailed description

This study is a multi-center randomized phase III trial to compare the failure free survival between those randomized to IST vs 9-10/10 HLA matched URD BMT. The study will also address patient-reported outcomes and gonadal function in each arm and explore critical biological correlates including assessing germline genetic mutations associated with pediatric SAA that may lead to a predisposition to the disease and the risk of development of clonal hematopoiesis following IST vs BMT in pediatric and young adult SAA.

This clinical trial will randomize 234 children/AYA over 3.3-4.7 years at a 1:1 ratio between initial treatment with immune suppression therapy (IST) with horse ATG (hATG)/cyclosporine (CsA) versus well- matched (9-10/10 allele) unrelated donor (URD) bone marrow transplantation (BMT) using a regimen of rabbit ATG (rATG)/fludarabine/cyclophosphamide and 200 cGy TBI. Duration of subject participation for all study procedures in this study will be up to 2 years after treatment; a single later timepoint between 3 and 5 years will be collected to follow patients for specific protocol defined late effects and survival.

03

Conditions studied

  • Severe Aplastic Anemia

Browse trials for

04

Who can participate

Ages eligible
0 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in the randomized trial, an individual must meet all the following criteria:

  1. Provision of signed and dated form for the randomized trial by patient and/or legal guardian.
  2. Age ≤25 years old at time of randomized trial consent.
  3. Confirmed diagnosis of idiopathic SAA, defined as:

    1. Bone marrow cellularity \<25%, or \<30% hematopoietic cells.
    2. Two of three of the following (in peripheral blood): neutrophils \<0.5 x 10\^9/L, \<20 x 10\^9/L, absolute reticulocyte count \<60 x 10\^9/L or \<8 g/dL.
  4. No suitable fully matched related donor available (minimum 6/6 match for HLA-A and B at intermediate or high resolution and DRB1 at high resolution using DNA based typing).
  5. At least 2 unrelated donors noted on NMDP search who are well matched (9/10 or 10/10 for HLA-A, B, C, DRB1, and DQB1 using high resolution).
  6. In the treating physician's opinion, no obvious precluding them from BMT or IST.

Exclusion criteria

Exclusion Criteria:

  1. Presence of Inherited bone marrow failure syndromes (IBMFS). The diagnosis of Fanconi anemia must be excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow. Telomere length testing should be sent on all patients to exclude Dyskeratosis Congenita (DC), but if results are delayed or unavailable and there are no clinical manifestations of DC, patients may enroll. If patients have clinical characteristics suspicious for Shwachman-Diamond syndrome, this disorder should be excluded by pancreatic isoamylase testing or gene mutation analysis (note: pancreatic isoamylase testing is not useful in children \<3). Other testing per center may be performed to exclude IBMFS.
  2. Clonal cytogenetic abnormalities or Fluorescence In-Situ Hybridization (FISH) pattern consistent with pre- myelodysplastic syndrome (pre-MDS) or MDS on marrow examination.
  3. Known severe allergy to ATG.
  4. Prior or autologous stem cell transplant.
  5. Prior solid organ transplant.
  6. Infection with (HIV).
  7. Active or C. This only needs to be excluded in patients where there is clinical suspicion of hepatitis (e.g., elevated LFTs).
  8. Female patients who are pregnant or breast-feeding.
  9. Prior except resected basal cell carcinoma or treated cervical carcinoma in situ.
  10. Disease modifying treatment prior to study enrollment, including but not limited to use of androgens, eltrombopag, romiplostim, or immune suppression. Note: Supportive care measures such as G-CSF, blood transfusion support and antibiotics are allowable
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Active comparator
    Immunosuppressive Therapy

    Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.

    Drug: cyclosporine · Drug: horse anti-thymocyte globulin (ATG) · Procedure: Immunosuppressive Therapy (IST)

  • Active comparator
    Matched Unrelated Stem Cell Transplant

    Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.

    Drug: cyclosporine · Procedure: Matched Unrelated Donor Hematopoetic Stem Cell Transplant · Drug: rabbit anti-thymocyte globulin (ATG) · Drug: Methotrexate · Drug: Fludarabine · Drug: Cyclophosphamide · Radiation: low-dose total body irradiation (TBI)

Interventions

  • cyclosporine

  • ProcedureMatched Unrelated Donor Hematopoetic Stem Cell Transplant

    Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)

  • DrugAntilymphocyte SerumStudies of Antilymphocyte SerumAntilymphocyte Serum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    horse anti-thymocyte globulin (ATG)

    Also known as: ATGAM

  • DrugThymoglobulinStudies of ThymoglobulinThymoglobulin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    rabbit anti-thymocyte globulin (ATG)

    Also known as: thymoglobulin

  • methotrexate

  • fludarabine

  • cyclophosphamide

  • Radiationlow-dose total body irradiation (TBI)

    low-dose total body irradiation (TBI)

  • ProcedureImmunosuppressive Therapy (IST)

    Immunosuppressive Therapy (IST)

06

What researchers measure

Primary outcomes

  1. The primary endpoint of this trial is time from randomization to treatment failure or death from any cause.

    The median time to failure or death will be compared on the two arms using the log-rank test. Failure of IST is defined as the date that a second definitive therapy was recommended (BMT, second course of ATG) and failure of BMT defined as the date that a second definitive therapy was recommended (second BMT, course of ATG).

    Time frame: Randomization to 2 years post-randomization

Secondary outcomes

  1. Comparison of subjects with failure of IST or BMT before or at 2 years

    The proportion of subjects with failure of IST or BMT before or at 2 years. Failure of IST is defined as initiation of a second definitive therapy (BMT, second course of ATG) and failure of BMT defined as initiation of a second definitive therapy (second BMT, course of ATG).

    Time frame: Randomization to 2 years post-randomization

  2. Comparison of subjects with inadequate counts at 2 years among those who have not died or failed treatment.

    The proportion of subjects with inadequate counts at 2 years among those who have not failed therapy or died. Adequate counts are defined as: Absolute Neutrophil Count (ANC) \>1 x 10\^9/L, Hemoglobin \>10g/dL, and Platelets \>50 x10\^9/L.

    Time frame: Randomization to 2 years post-randomization

  3. Comparison of subjects on immune suppression therapy at 2 years among those who have not died or failed treatment.

    The proportion of subjects on immune suppression therapy at 2 years among those who have not failed therapy or died. Immune suppression is defined as systemic therapies necessary to treat SAA or GVHD (cyclosporine, tacrolimus, etc.). Isolated treatment with topical agents will not be considered as immune suppression therapy.

    Time frame: Randomization to 2 years post-randomization

  4. Estimate the time from randomization to initiation of IST or BMT.

    The median time in days from randomization to initiation of IST or BMT will be estimated. Initiation of therapy is first day of ATG for IST subjects, or day 0 (infusion day) for bone marrow transplant subjects.

    Time frame: Randomization through Day 100

  5. Comparison of the frequency of failure to receive primary assigned therapy (IST or BMT) and reasons for the failure.

    The proportion of subjects who fail to receive randomized therapy and the frequency of reasons for failure.

    Time frame: Randomization through Day 100

  6. Comparison of the incidence of bacteremia, viremia, and invasive fungal infection in the first two years after randomization in the IST and BMT arms.

    Proportion of subjects from the time of randomization in the first 2 years with each of the following: 1. Documented bacteremia 2. Documented viremia 3. Documented invasive fungal infection (defined as confirmed or suspected fungal infection based upon imaging)

    Time frame: Randomization through two years post randomization

  7. Estimate the median time to T- and B-cell immune reconstitution the first year for the URD BMT Arm

    Absolute CD3, CD4, CD8, CD19, and CD56 (NK cell) numbers will be tracked at 100 days, 180 days, 1 year and 2 years post initiation of therapy in URT BMT arm. IgG levels free of IVIG replacement will be collected at the same timepoints. The median time to T- and B-cell reconstitution will be estimated.

    Time frame: Initiation of therapy (Day 0) to 100 days, 180 days, 1 year and 2 years

  8. Comparison of overall survival at 1 and 2 years from randomization in both arms.

    Proportion of subjects who have died at 1 year and 2 years after randomization for any reason.

    Time frame: Randomization to one year, randomization to two years

  9. Comparison of treatment-related mortality (TRM) at 1 and 2 years from randomization in both arms.

    Proportion of subjects who have died at 1 year and 2 years after randomization due to treatment-related reasons. TRM is defined as death in recipients without relapse or progression of their disease. Non-medical, accidental causes of death, e.g., natural disasters, are not considered TRM.

    Time frame: Randomization to 1 year, randomization to 2 years

  10. Comparison of the median time from randomization to and rates of neutrophil recovery on both arms

    The time from randomization to neutrophil recovery. Neutrophil recovery is defined as ANC 0.5 x109/L for 3 consecutive measures for neutrophils (recovery date is the first date).

    Time frame: Randomization to 100 days, 180 days, 1 year and 2 years

  11. Comparison of the median time from randomization to and rate of platelet recovery on both arms

    The time from randomization to platelet recovery. Platelet recovery is defined as platelet levels \>= 20 x10\^9/L for 3 consecutive measures (recovery is the first date) with no platelet transfusions for 1 full week.

    Time frame: Randomization to 100 days, 180 days, 1 year and 2 years

  12. Comparison of the median time from randomization to and rates of red blood cell recovery on both arms

    The time from randomization to red blood cell recovery. Red blood cell recovery is defined as RBC hemoglobin level \>= 8g/dL and 10g/dL with no RBC transfusions for 4 weeks.

    Time frame: Randomization to 100 days, 180 days, 1 year and 2 years

  13. Comparison of the median time from initiation of therapy to and rates of neutrophil recovery on both arms

    The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to neutrophil recovery. Neutrophil recovery is defined as ANC 0.5 x109/L for 3 consecutive measures for neutrophils (recovery date is the first date).

    Time frame: Initiation of therapy to 100 days, 180 days, 1 year and 2 years

  14. Comparison of the median time from initiation of therapy to and rate of platelet recovery on both arms

    The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to platelet recovery. Platelet recovery is defined as platelet levels \>= 20 x10\^9/L for 3 consecutive measures (recovery is the first date) with no platelet transfusions for 1 full week.

    Time frame: Initiation of therapy to 100 days, 180 days, 1 year and 2 years

  15. Comparison of the median time from initiation of therapy to and rates of red blood cell recovery on both arms.

    The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to red blood cell recovery. Red blood cell recovery is defined as RBC hemoglobin level \>= 8g/dL and 10g/dL with no RBC transfusions for 4 weeks.

    Time frame: Randomization to 100 days, 180 days, 1 year and 2 years

  16. Estimate the rates of engraftment in patients who are randomized to URD BMT.

    Proportion of subjects with engraftment in patients who receive URD BMT.

    Time frame: Randomization to 3-5 years

  17. Estimate the rates of primary graft failure in patients who are randomized to URD BMT .

    Proportion of subjects with primary graft failure in patients who receive URD BMT. Primary graft failure is defined as failure to achieve neutrophil recovery by Day +28 following a conditioning regimen induced neutrophil nadir \< 0.5 x10\^9/L.

    Time frame: Randomization to 3-5 years

  18. Estimate the rates of secondary graft failure in patients who are randomized to URD BMT .

    Proportion of subjects with secondary graft failure in patients who receive URD BMT. Secondary graft failure will be defined as a fall in the neutrophil count after documented primary engraftment to \< 0.5 x10\^9/L sustained for more than three days that cannot be attributed to other causes such as drugs, infection, GVHD, etc., and is not responsive to G-CSF or GM-CSF.

    Time frame: Randomization to 3-5 years

  19. Estimate the rates of grade II-IV acute GVHD in patients who are randomized to URD BMT .

    Proportion of subjects with grade II-IV in patients who receive URD BMT.

    Time frame: Randomization to 3-5 years

  20. Estimate the rates of grade III-IV acute GVHD in patients who are randomized to URD BMT.

    Proportion of subjects with grade III-IV acute GVHD in patients who receive URD BMT.

    Time frame: Randomization to 3-5 years

  21. Estimate the rates of severe chronic GVHD in patients who are randomized to URD BMT.

    Proportion of subjects with severe chronic GVHD in patients who receive URD BMT.

    Time frame: Randomization to 3-5 years

  22. Estimate the rates of response of patients randomized to IST

    Proportion of subjects with IST response. IST response criteria is: Complete Response: Hemoglobin ≥10 g/dL and ANC ≥1x10\^9/L and Platelets ≥100x10\^9/L Very Good Partial Response: Hemoglobin ≥8 g/dL and ANC ≥0.5x10\^9/L and Platelets ≥50x10\^9/L Partial Response: Hemoglobin ≥8 g/dL and ANC ≥0.5x10\^9/L and Platelets ≥20x10\^9/L and transfusion independent No Response (failure): Hemoglobin \<8 g/dL or ANC \<0.5x10\^9/L or Platelets \<20x10\^9/L Lost Response: A lost response is captured by not meeting hematologic response criteria at a particular time point after having an initial response (complete, very good partial, or partial), or the need for additional treatment.

    Time frame: Randomization to 100 days, 180 days, 1 year and 2 years

  23. Estimate the rates of failure of patients randomized to IST

    Proportion of subjects with IST failure at 6 months (defined as Hemoglobin \<8 g/dL or ANC \<0.5x10\^9/L or Platelets \<20x10\^9/L).

    Time frame: Randomization to 100 days, 180 days, 1 year and 2 years

  24. Describe the secondary therapies given and outcomes achieved for patients failing initial therapy

    Collect secondary therapies given for failure of primary randomized therapy (BMT after IST, second course of IST, second BMT). For the outcome after subsequent therapy, the median survival time will be estimated.

    Time frame: Randomization to 3-5 years

  25. Comparison of rates of secondary MDS, AML, other subsequent neoplasms, and development of Paroxysmal Nocturnal Hemoglobinuria in both treatment arms for the duration of the trial.

    Proportion of subjects in each treatment arm with i) subsequent neoplasms, ii) presence of a PNH clone at time of randomization who go on to develop symptomatic PNH through the duration of the protocol.

    Time frame: Randomization to 3-5 years

  26. Comparison of HR-QoL score between patients randomized to both arms

    Change in score between baseline and two years and the trajectory of change over all timepoints.

    Time frame: Randomization to 2 years post-randomization, randomization to up to 5 years post-randomization

  27. Comparison of gonadal function values between patients randomized to both arms

    Proportion of subjects with gonadal function values outside the expected percentile for that age.

    Time frame: Randomization to 1 year post-randomization, randomization to 2 years post-randomization, and randomization to up to 5 years post-randomization

07

Study locations

52 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Arkansas
    Little Rock, Arkansas 72202, United States
  • Loma Linda
    Loma Linda, California 92354, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • UCLA
    Los Angeles, California 90095, United States
  • Children's Hospital & Research Center Oakland
    Oakland, California 94609, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Stanford
    Palo Alto, California 94304, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • Nemours Children's Hospital, Delaware
    Wilmington, Delaware 19803, United States
  • Children's National Hospital
    Washington D.C., District of Columbia 20010, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • Johns Hopkins All Children's Hospital
    St. Petersburg, Florida 33701, United States
  • Children's Hospital of Atlanta/Emory
    Atlanta, Georgia 30322, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Indiana University Hospital/Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Children's Hospital NOLA
    New Orleans, Louisiana 70118, United States
  • Maine Health
    Scarborough, Maine 04074, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Helen DeVos Children's Hospital
    Grand Rapids, Michigan 49503, United States
  • Mayo Clinic Rochestser
    Rochester, Minnesota 55902, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Washington University in St. Louis
    St Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14263, United States
  • Cohen Children's Medical Center of New York
    New Hyde Park, New York 11040, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Levine Children's Hospital
    Charlotte, North Carolina 28203, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37203, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Methodist Healthcare
    San Antonio, Texas 78229, United States
  • University of Utah/Primary Children's Hospital
    Salt Lake City, Utah 84112, United States
  • Children's Hospital of the King's Daughter
    Norfolk, Virginia 23507, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • British Columbia Children's
    Vancouver, British Columbia V6H 3V4, Canada
  • Winnipeg CancerCare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2023 to primary completion in Aug 2026, 42 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2029 → Aug 2026 and completion Dec 2029 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Oct 31, 2022
StartActual
Jan 25, 2023
Primary completionActual
Aug 6, 2026was Dec 2029
CompletionActual
Aug 6, 2026was Dec 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Funding terminated
changed Oct 19, 2026
Primary completion
Dec 2029→Aug 6, 2026 (actual)
Oct 19, 2026
Study completion
Dec 2029→Aug 6, 2026 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Terminated
    Why stopped Funding terminated
    Primary completion Dec 2029→Aug 6, 2026 (now actual)
    Study completion Dec 2029→Aug 6, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05600426
Collaborators
Center for International Blood and Marrow Transplant Research, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), North American Pediatric Aplastic Anemia Consortium, Pediatric Transplantation and Cellular Therapy Consortium, Blood and Marrow Transplant Clinical Trials Network
Responsible party
David Williams (Chief - Division of Hematology/Oncology, Boston Children's Hospital) — Principal investigator
First posted
Oct 31, 2022
Start date
Jan 25, 2023
Primary completion
Aug 6, 2026
Completion
Aug 6, 2026
Last update
Oct 19, 2026

Study contacts

David Williams, MD
principal investigator · Boston Children's Hospital
Michael Pulsipher, MD
principal investigator · University of Utah
Bronwen Shaw, MD
principal investigator · CIBMTR/Medical College of Wisconsin (MCW)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antilymphocyte Serum · Thymoglobulin · Methotrexate · Fludarabine · Cyclophosphamide

Start the discussion